TrialAnnals of neurology2026

Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single-Arm Clinical Trial.

Lilyana Amezcua et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.